Semaglutide and Tirzepatide are both incretin-based therapies, primarily utilized for weight management and metabolic health improvements. Semaglutide, a GLP-1 receptor agonist, has been shown in our corpus to achieve significant weight loss, with evidence suggesting that oral formulations can achieve exposure similar to subcutaneous injections and lead to greater weight loss in simulated studies. Tirzepatide, a dual GLP-1R/GIPR agonist, also demonstrates substantial weight loss benefits and broader health benefits beyond diabetes and weight loss, including potential multi-organ protection. Both peptides are associated with improvements in metabolic parameters, and evidence suggests that combining them with exercise or tailored dietary strategies can enhance their efficacy.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist, gip agonist |
| Studies in corpus | 1011 | 722 |
| Highest evidence tier | — | — |
| Evidence tier mix | n/a | n/a |
| Studies with explicit sample size | 0 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Semaglutide and Tirzepatide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 941 Semaglutide batches across 307 manufacturers, 99.54% avg purity.
We tested 7722 Tirzepatide batches across 1544 manufacturers, 99.69% avg purity.
We hold deeper lab coverage on Tirzepatide (7722 batches tested). Tirzepatide edges ahead on average measured purity (99.54% vs 99.69%) — a narrow gap; weigh it against failed-batch and underdose counts above.
No direct head-to-head trials in our corpus. Indirect comparison only. While both are incretin agonists, Tirzepatide is a dual GLP-1R/GIPR agonist, which a review suggests may offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglutide by enhancing GLP-1's therapeutic potential. Head-to-head studies in our corpus, though future-dated, aim to compare their impact on genetic aging in obese adults and their real-world effectiveness in preventing Major Cardiovascular Events in Type 2 Diabetes. One cohort study suggests that Tirzepatide may offer substantial weight-loss benefits in patients with rheumatic and musculoskeletal diseases. Our corpus also includes a meta-analysis clarifying the link between semaglutide and non-arteritic anterior ischemic optic neuropathy risk, which is critical for patient counseling. For Tirzepatide, a comprehensive analysis strengthens evidence for its potential as a multi-organ protective agent, extending its utility beyond metabolic control, including for cardiovascular disease, chronic kidney disease, and non-alcoholic fatty liver disease (NAFLD).
Looking for vendor-level purity, endotoxin, and HPLC data on Semaglutide or Tirzepatide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.